PACBPacific Biosciences of California, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Overbought (RSI 70). Price is +45% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PACB is trading
Pacific Biosciences of California, Inc. is +64% over the past year while the S&P 500 is +18%: 46 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +45%
vs 200-day average · a clear uptrend
- RSI (14)
- 70
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 20%
Below its 52-week high
Details›
- Last close2026-10-08
- $2.30
- 1 monthS&P 500 +1.6%
- +79%
- 1 yearS&P 500 +18%
- +64%
- 5 yearsS&P 500 +86%
- −91%
- vs 50-day average$1.52
- +51%
- 52-week high
- $2.88
- 52-week low
- $1.11
- Annualised volatility
- 96%
| Year | Return |
|---|---|
| 2026 (year to date) | +23% |
| 2025 | +2.2% |
| 2024 | −81% |
| 2023 | +20% |
| 2022 | −60% |
| 2021 | −21% |
| 2020 | +405% |
| 2019 | −31% |
| 2018 | +180% |
| 2017 | −31% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +0.51% |
| Feb | 10 | 3 of 10 | −9.7% |
| Mar | 10 | 3 of 10 | −8.2% |
| Apr | 10 | 4 of 10 | −7.8% |
| May | 10 | 3 of 10 | −3.6% |
| Jun | 10 | 6 of 10 | +7.0% |
| Jul | 11 | 5 of 11 | +4.8% |
| Aug | 11 | 5 of 11 | +12% |
| Sep | 11 | 6 of 11 | +11% |
| Oct | 11 | 5 of 11 | +10% |
| Nov | 10 | 5 of 10 | +11% |
| Dec | 10 | 2 of 10 | −5.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.